Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Forte Biosciences, Inc. (TOCA)
|
Add to portfolio |
|
|
|
| Price: |
$34.65
| | Metrics |
| OS: |
36.3
|
M
| |
|
|
| Market cap: |
$1.26
|
B
| |
|
|
|
Net cash:
|
$30.4
|
M
| |
$0.84
|
per share
|
|
EV:
|
$1.23
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 18.0 | 0.0 | 0.0 | 0.1 |
| Revenue growth | | | | -100.0% | 43890.2% | -16.3% | -3.9% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 18.0 | 0.0 | 0.0 | 0.1 |
| Gross margin | | | | | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 13.9 | 21.5 | | | | | | |
| Research and development | 5.6 | 13.9 | 10.0 | 2.7 | 51.1 | 29.1 | 27.2 | 19.2 |
| General and administrative | | | 4.2 | 1.4 | 12.8 | 8.6 | 4.5 | 3.8 |
| EBIT | 0.0 | 0.0 | -14.2 | -4.1 | -45.9 | -37.6 | -31.7 | -23.0 |
| EBIT margin | | | | | -254.2% | -91775.6% | -64673.5% | -45007.8% |
| Pre-tax income | -13.9 | -21.7 | -46.5 | -4.1 | -47.3 | -38.9 | -33.5 | -23.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 1.7 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | | | | 0.0% |
| Net income | -13.9 | -21.7 | -46.5 | -4.1 | -49.0 | -38.9 | -33.5 | -23.1 |
| Net margin | | | | | -271.4% | -94948.8% | -68322.4% | -45207.8% |
| |
| Diluted EPS | ($0.80) | ($1.55) | ($6.32) | ($1.93) | ($2.44) | ($2.66) | ($15.22) | ($10.57) |
| Shares outstanding (diluted) | 17.4 | 14.0 | 7.4 | 2.1 | 20.1 | 14.6 | 2.2 | 2.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|